New melanoma drug based on herpes virus granted FDA accelerated approval

Federal regulators have granted accelerated approval to a novel oncolytic virus therapy for advanced melanoma, providing physicians with an innovative treatment option for this aggressive skin cancer. This groundbreaking medication harnesses a modified herpes virus to target and destroy melanoma cells while stimulating the immune system. The accelerated approval pathway reflects the therapy's potential to significantly improve outcomes for patients with advanced disease who have limited treatment alternatives. This approval represents a major advancement in melanoma treatment, offering hope to patients battling one of the most dangerous forms of skin cancer.